RAF1 Gene Fusions as a Possible Driver Mechanism in Rare BAP1-Inactivated Melanocytic Tumors: A Report of 2 Cases

Michele Donati1,2, Petr Martinek2,3, Liubov Kastnerova2,3

  • 1Department of Pathology, University Hospital Campus Bio-Medico, Rome, Italy.

Insights

BRCA1-associated protein (BAP1)-inactivated melanocytic tumors (BIMTs) can have RAF1 fusions, not just BRAF mutations. This finding expands the known genetic landscape of these rare skin neoplasms.

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • BRCA1-associated protein (BAP1)-inactivated melanocytic tumor (BIMT) are rare epithelioid melanocytic neoplasms.
  • BIMTs are characterized by BAP1 tumor suppressor gene loss-of-function.
  • These tumors can occur sporadically or as part of a hereditary cancer syndrome.

Observation:

  • Most BIMTs are associated with BRAF-mutated melanocytic nevi.
  • Previous studies reported BRAF or NRAS mutations, or no driver mutation.
  • This study identified RAF1 fusions in two BIMT cases.

Findings:

  • The two reported BIMTs had BAP1 mutations and RAF1 fusions.
  • These lesions were wild type for BRAF and NRAS mutations.
  • The tumors were associated with conventional melanocytic nevi with dysplastic junctional features.

Implications:

  • RAF1 fusions may represent a driver genetic event in a subset of BIMTs.
  • This expands the known molecular spectrum of BIMTs.
  • Understanding these genetic alterations is crucial for diagnosis and potential therapeutic strategies.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.5K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K